Pressure Biosciences INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OTC.Pink
Director Jeffrey N. Peterson acquired 59,652 shares of Pressure BioSciences Inc. (PBIO) common stock on September 27, 2024, through interest paid on convertible preferred stock.
OTC.Pink
Richard T. Schumacher, President and CEO of Pressure BioSciences Inc, acquired 22,878 shares of common stock on September 27, 2024, through interest paid on convertible preferred stock.
OTC.Pink
Director Michael S Urdea acquired 14,429 shares of Pressure BioSciences Inc. common stock on September 27, 2024, through interest payment on convertible preferred stock.
OTC.Pink
Director Alexander V. Lazarev acquired 18,863 shares of Pressure BioSciences Inc. as interest on convertible preferred stock.
OTC.Pink
Director Michael S Urdea acquired 2,872 shares of Pressure BioSciences Inc. common stock on March 27, 2024, through interest paid on convertible preferred stock.
OTC.Pink
Richard T. Schumacher, President and CEO of Pressure BioSciences Inc, acquired 4,554 shares of common stock on March 27, 2024, through interest paid on convertible preferred stock.
OTC.Pink
Kevin Pollack, a director at Pressure BioSciences Inc, acquired 2,914 shares of common stock on March 27, 2024, through interest paid on convertible preferred stock.
OTC.Pink
Director Jeffrey N. Peterson acquired 11,874 shares of Pressure BioSciences Inc. (PBIO) common stock on March 27, 2024, through interest paid on convertible preferred stock.
OTC.Pink
Vito J. Mangiardi, a director at Pressure BioSciences Inc, acquired 625 shares of common stock on March 27, 2024, through interest paid on convertible preferred stock.
OTC.Pink
Director Alexander V. Lazarev acquired 3,755 shares of Pressure BioSciences Inc. as interest on convertible preferred stock.